WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596719

CAS#: 491869-01-3

Description: L-826141 is a phosphodiesterase 4 (PDE4) inhibitor.

Chemical Structure

CAS# 491869-01-3

Theoretical Analysis

MedKoo Cat#: 596719
Name: L-826141
CAS#: 491869-01-3
Chemical Formula: C25H19F10NO4
Exact Mass: 587.1154
Molecular Weight: 587.41
Elemental Analysis: C, 51.12; H, 3.26; F, 32.34; N, 2.38; O, 10.89

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: L-826141; L 826141; L826141; L-826,141; L 826,141; L826,141;

IUPAC/Chemical Name: 4-(2-(3,4-bis(difluoromethoxy)phenyl)-2-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)ethyl)-3-methylpyridine 1-oxide


InChi Code: InChI=1S/C25H19F10NO4/c1-13-12-36(38)9-8-15(13)10-18(16-4-7-19(39-21(26)27)20(11-16)40-22(28)29)14-2-5-17(6-3-14)23(37,24(30,31)32)25(33,34)35/h2-9,11-12,18,21-22,37H,10H2,1H3

SMILES Code: OC(C(F)(F)F)(C(F)(F)F)C1=CC=C(C(C2=CC=C(OC(F)F)C(OC(F)F)=C2)CC3=CC=[N+]([O-])C=C3C)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 587.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol. 2008 Oct;155(3):288-90. doi: 10.1038/bjp.2008.297. Epub 2008 Jul 28. PubMed PMID: 18660832; PubMed Central PMCID: PMC2567889.

2: Moore CS, Earl N, Frenette R, Styhler A, Mancini JA, Nicholson DW, Hebb AL, Owens T, Robertson GS. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan -2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther. 2006 Oct;319(1):63-72. Epub 2006 Jun 29. PubMed PMID: 16809479.

3: Lavoie JP, Pasloske K, Joubert P, Cordeau ME, Mancini J, Girard Y, Friesen RW, Frenette R, Blouin M, Young RN, Hickey G. Lack of clinical efficacy of a phosphodiesterase-4 inhibitor for treatment of heaves in horses. J Vet Intern Med. 2006 Jan-Feb;20(1):175-81. PubMed PMID: 16496938.

4: Liu S, Veilleux A, Zhang L, Young A, Kwok E, Laliberté F, Chung C, Tota MR, Dubé D, Friesen RW, Huang Z. Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. J Pharmacol Exp Ther. 2005 Aug;314(2):846-54. Epub 2005 May 18. PubMed PMID: 15901792.

5: Claveau D, Chen SL, O'Keefe S, Zaller DM, Styhler A, Liu S, Huang Z, Nicholson DW, Mancini JA. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan- 2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther. 2004 Aug;310(2):752-60. Epub 2004 Apr 13. PubMed PMID: 15082748.

6: Frenette R, Blouin M, Brideau C, Chauret N, Ducharme Y, Friesen RW, Hamel P, Jones TR, Laliberté F, Li C, Masson P, McAuliffe M, Girard Y. Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters. Bioorg Med Chem Lett. 2002 Oct 21;12(20):3009-13. PubMed PMID: 12270195.

7: Muise ES, Chute IC, Claveau D, Masson P, Boulet L, Tkalec L, Pon DJ, Girard Y, Frenette R, Mancini JA. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors. Biochem Pharmacol. 2002 Apr 15;63(8):1527-35. PubMed PMID: 11996895.